Loading…
Loading…
Accelerant Holdings NYSE: ARX jumped into view for investors in mid-August after its shares surged 43% in a single day. This type of share price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, not for an unglamorous firm connecting specialty insurance risk across a network of capital providers.
Accelerant Holdings (NYSE: ARX - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $13.76 and traded as high as $19.78. Accelerant shares last traded at $19.77, with a volume of 1,488,977 shares changing hands. Analyst Upgrades and Downgrades A number
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - CHMI, VREX, HHS and ARX PR Newswire
Accelerant Holdings (ARX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
ARX is going private just over a year after its IPO, as Thoma Bravo's $4 billion deal capitalizes on stronger operating results.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos